These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

720 related items for PubMed ID: 12601452

  • 1. [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.
    Berding G, Brücke T, Odin P, Brooks DJ, Kolbe H, Gielow P, Harke H, Knoop BO, Dengler R, Knapp WH.
    Nuklearmedizin; 2003 Feb; 42(1):31-8. PubMed ID: 12601452
    [Abstract] [Full Text] [Related]

  • 2. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
    Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, Virgolini I, Wenning GK, Poewe W.
    Brain; 2005 Jul; 128(Pt 7):1605-12. PubMed ID: 15817519
    [Abstract] [Full Text] [Related]

  • 3. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy.
    Knudsen GM, Karlsborg M, Thomsen G, Krabbe K, Regeur L, Nygaard T, Videbaek C, Werdelin L.
    Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1631-8. PubMed ID: 15583914
    [Abstract] [Full Text] [Related]

  • 4. 99mTc-TRODAT-1 imaging of multiple system atrophy.
    Lu CS, Weng YH, Chen MC, Chen RS, Tzen KY, Wey SP, Ting G, Chang HC, Yen TC.
    J Nucl Med; 2004 Jan; 45(1):49-55. PubMed ID: 14734673
    [Abstract] [Full Text] [Related]

  • 5. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy.
    Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP.
    Mov Disord; 2001 Nov; 16(6):1023-32. PubMed ID: 11748733
    [Abstract] [Full Text] [Related]

  • 6. Analysis of Extrastriatal 123I-FP-CIT Binding Contributes to the Differential Diagnosis of Parkinsonian Diseases.
    Joling M, Vriend C, van den Heuvel OA, Raijmakers PGHM, Jones PA, Berendse HW, Booij J.
    J Nucl Med; 2017 Jul; 58(7):1117-1123. PubMed ID: 27856628
    [Abstract] [Full Text] [Related]

  • 7. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wöber C, Müller C, Podreka I.
    J Neural Transm Suppl; 1997 Jul; 50():9-24. PubMed ID: 9120429
    [Abstract] [Full Text] [Related]

  • 8. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.
    Kim SE, Choi JY, Choe YS, Choi Y, Lee WY.
    J Nucl Med; 2003 Jun; 44(6):870-6. PubMed ID: 12791812
    [Abstract] [Full Text] [Related]

  • 9. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
    Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T, Lang AE.
    Mov Disord; 2002 Mar; 17(2):303-12. PubMed ID: 11921116
    [Abstract] [Full Text] [Related]

  • 10. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, van Dyck CH, Innis RB.
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [Abstract] [Full Text] [Related]

  • 11. SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity.
    Kim SE, Lee WY, Choe YS, Kim JH.
    Neurol Res; 1999 Apr; 21(3):255-61. PubMed ID: 10319333
    [Abstract] [Full Text] [Related]

  • 12. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Antonini A, Benti R, De Notaris R, Tesei S, Zecchinelli A, Sacilotto G, Meucci N, Canesi M, Mariani C, Pezzoli G, Gerundini P.
    Neurol Sci; 2003 Oct; 24(3):149-50. PubMed ID: 14598060
    [Abstract] [Full Text] [Related]

  • 13. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
    Pirker W.
    Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
    [Abstract] [Full Text] [Related]

  • 14. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.
    Fischman AJ, Bonab AA, Babich JW, Palmer EP, Alpert NM, Elmaleh DR, Callahan RJ, Barrow SA, Graham W, Meltzer PC, Hanson RN, Madras BK.
    Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103
    [Abstract] [Full Text] [Related]

  • 15. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, Charney DS, van Dyck CH, Hoffer PB, Innis RB.
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [Abstract] [Full Text] [Related]

  • 16. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC.
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [Abstract] [Full Text] [Related]

  • 17. Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease.
    Swanson RL, Newberg AB, Acton PD, Siderowf A, Wintering N, Alavi A, Mozley PD, Plossl K, Udeshi M, Hurtig H.
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):302-7. PubMed ID: 15791439
    [Abstract] [Full Text] [Related]

  • 18. [Dopamine transporter SPECT in patients with Parkinson's disease].
    Hamano T, Tsuchida T, Hirayama M, Fujiyama J, Mutoh T, Yonekura Y, Kuriyama M.
    Kaku Igaku; 2000 Mar; 37(2):125-9. PubMed ID: 10783572
    [Abstract] [Full Text] [Related]

  • 19. SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease.
    Eising EG, Müller TT, Zander C, Kuhn W, Farahati J, Reiners C, Coenen HH.
    J Investig Med; 1997 Oct; 45(8):448-52. PubMed ID: 9394097
    [Abstract] [Full Text] [Related]

  • 20. [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients.
    Haapaniemi TH, Ahonen A, Torniainen P, Sotaniemi KA, Myllylä VV.
    Mov Disord; 2001 Jan; 16(1):124-30. PubMed ID: 11215571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.